Table 5.
Remission Rates for Select Antidepressants in Age & Gender Subgroups
| Age & Gender Groups | Bupropion | Citalopram | Desvenlafaxine | Escitalopram | Fluoxetine | Sertraline | Venlafaxine |
|---|---|---|---|---|---|---|---|
| Age: 13-19 Female | 6.68% (19,891) | 28.39% (25,292) | 28.25% (1,586) | 13.75% (40,046) | 26.25% (50,572) | 29.85% (58,857) | 29.9% (11,264) |
| Age: 13-19 Male | 5.29% (16,243) | 25.05% (12,475) | 26.45% (726) | 13.92% (19,697) | 24.72% (25,261) | 26.88% (30,690) | 26.29% (5,572) |
| Age: 20-40 Female | 5.59% (191,664) | 42.94% (169,331) | 43.98% (17,933) | 18.09% (220,077) | 40.6% (200,708) | 45.5% (277,958) | 45.31% (104,843) |
| Age: 20-40 Male | 5.84% (79,494) | 41.38% (66,637) | 41.37% (6263) | 18.8% (88,852) | 39.1% (54,677) | 42.21% (92,840) | 42.62% (38,943) |
| Age: 41-64 Female | 6.35% (305,046) | 52.12% (278,067) | 51.51% (30,090) | 22.84% (315,428) | 50.24% (294,013) | 54.33% (342,158) | 51.05% (200,900) |
| Age: 41-64 Male | 6.97% (134,314) | 50.78% (114,603) | 46.87% (9,766) | 22.83% (131,628) | 49.66% (85,883) | 52.27% (139,402) | 49.89% (64,838) |
| Age: 65-79 Female | 6.36% (44,203) | 55.11% (97,030) | 52.92% (3,987) | 22.58% (84,940) | 58.61% (59,520) | 58.43% (109,590) | 54.6% (37,979) |
| Age: 65-79 Male | 6.71% (22,908) | 55.66% (38,491) | 49.74% (1,512) | 22.45% (34,205) | 57.3% (21,185) | 58.1% (45,521) | 54.04% (14,118) |
| Age: 80-89 Female | 6.12% (4,872) | 44.28% (26,382) | 54.68% (406) | 16.63% (23,604) | 48.91% (9,073) | 49.02% (32,855) | 48.57% (6053) |
| Age: 80-89 Male | 5.57% (2,387) | 46.57% (9,659) | 54.07% (135) | 17.27% (8,611) | 48.73% (3,587) | 51.45% (12,973) | 52.34% (2052) |
Cell values show percent of patients experiencing remission. Number of treatment episodes receiving the antidepressant is given in parentheses. Best remission rates are in bold. Within the age and gender group, bold antidepressants are significantly (alpha<0.05) better than non-bold ones. Full report of monotherapy with 15 antidepressants is available in online supplement.